🧭 MACRO CONTEXT
Equity futures are pointing higher this morning as oil prices retreat from recent highs, easing near-term inflation pass-through concerns even as the 10-year Treasury sits at 4.45% (FRED) and headline CPI YoY prints at 330.293 index level (FRED — note: this is the index level, not the inflation rate; underlying YoY change requires comparison to prior reading). Unemployment at 4.3% and real GDP growth at 2.0% (FRED) describe a labor market that is loosening at the margin but not breaking, and a real economy that is decelerating but not contracting — the textbook "soft landing" backdrop, though I remain skeptical until we see the next two CPI prints. The S&P 500 at 7,259 (FRED) reflects a market that has fully repriced the AI capex cycle and given little margin for disappointment.
The dominant overnight thread is Palantir's Q1 print: revenue +85% YoY, with US business booming (Yahoo Finance, CNBC). Shares slipped post-print despite the headline beat — a classic "priced-to-perfection" reaction that I'll dig into in the portfolio section. Coinbase cutting 14% of headcount citing "AI acceleration" with shares gaining (CNBC) is a meaningful tell: capital markets are now actively rewarding AI-driven labor compression, which has direct read-through to my software theses (WDAY, PCTY, PAYC) where AI displacement of HCM/payroll headcount is the central bear case I've been monitoring. AMD reports tonight (MarketWatch) — a critical read on AI semis demand sustainability post-NVDA's recent volatility.
Geopolitically, Middle East tensions remain in focus driving oil volatility (CNBC). The "Trump's heavy hand on AI" framing (Axios) is worth tracking — any executive action on AI export controls, model regulation, or chip restrictions would have first-order impact on NVDA, MSFT, and second-order impact across my software book.
📊 PORTFOLIO THESIS UPDATE
MSFT (Conviction 8/10 — RECOMMEND, unchanged): No new fundamental data. The Coinbase AI-driven headcount cut narrative is incrementally supportive of MSFT's Copilot monetization thesis — enterprise willingness to pay for AI productivity tools is being validated by the demand side (companies cutting labor) not just the supply side (vendors selling seats). Holding 8/10.
NVDA (Conviction 8/10 — RECOMMEND, unchanged): "Institutions Keep Buying NVIDIA" headline (source: aggregator, low signal) is not a thesis input. AMD print tonight is the real catalyst — if AMD shows DC GPU acceleration, it's a positive demand signal for the AI compute market broadly; if AMD disappoints, watch for share-shift narrative back to NVDA. No conviction change.
MELI (Conviction 7/10 — RECOMMEND, unchanged): BTIG/Jefferies bullish despite margin pressures (Yahoo Finance) — consistent with my thesis that near-term margin compression from logistics/fintech investment is the right strategic call. Analyst sentiment is an input, not a conclusion. Holding.
FSLR (Conviction 7/10 — MONITORING): +15% week, +14% month with no thesis-relevant news. Price action without fundamental catalyst — I will not chase. Likely IRA-policy or solar capex sentiment driven. Awaiting Q2 earnings to validate.
LLY (Conviction 7/10 — MONITORING): +16% week is significant. Trial success on weight-loss pill (oral GLP-1) is a genuine fundamental catalyst — Truist reaffirms Buy (Yahoo Finance). Cramer endorsement is noise. The oral formulation, if approved, materially expands TAM vs. injectable competition (NVO). Considering upgrade to RECOMMEND pending review of trial efficacy data vs. NVO's pipeline. Conviction unchanged at 7/10 today; flagging for upgrade review this week.
TTD (Conviction 6/10 — MONITORING): +19% month. Wedbush upgrade from Underperform (Yahoo Finance) is a meaningful sentiment shift but a single-firm rating change is not a thesis input. The relevant question is whether the CTV ad market and TTD's competitive position vs. Amazon DSP have actually inflected — I do not have that data yet. Conviction unchanged.
DDOG (Conviction 6/10 — MONITORING): +25% month, earnings imminent. The "GRR can mask decay" article (referenced in WDAY context) is the right framework — I want to see net new logo adds and large-customer ($100K+) growth, not just NRR.
KNSL (Conviction 7/10 — MONITORING): -8% week, -12% month. No news flow. E&S softening cycle concerns persist. Need to validate Q1 submission count and rate trends before any conviction change.
RYAN (Conviction 6/10 — MONITORING): -13% week. News feed is unrelated (Ryan Cohen / GameStop). Real concern: the broader specialty insurance space is signaling cycle pressure (KNSL also weak). This is a yellow flag — monitoring for fundamental confirmation.
PAYC, HUBS, ZS, OKE, XOM: All recently auto-screened, no new thesis-changing data. Holding at 6/10 monitoring.
🔍 NEW RESEARCH / WATCHLIST ADDITIONS
No new additions today. Pipeline currently at 40+ monitored names — I am at appropriate breadth. Near-term focus is converting MONITORING names to either RECOMMEND or DROP based on Q1 earnings data flowing through this week.
Active upgrade candidates under review:
- LLY → potential RECOMMEND on oral GLP-1 trial data validation
- CEG → strong price action (+18% month) demands fundamental review on data center power demand contracts
- NET → +15% week, +13% month; need to validate Q1 metrics before chasing
⚠️ RISKS & RED FLAGS
AMD earnings tonight (MarketWatch) — bearish print would cascade into NVDA sentiment regardless of NVDA's actual fundamentals. Thesis unchanged either way unless data center GPU demand commentary shows real deceleration.
PLTR post-earnings weakness despite +85% revenue growth (Yahoo Finance) signals the AI-software valuation ceiling is being tested. Read-through to MSFT, DDOG, NET — if elite AI-revenue growers can't hold valuation, mid-tier names face derate risk.
RYAN -13% week with no public news — specialty insurance cycle softening is the most plausible explanation. If KNSL Q1 confirms rate deceleration, both names go to conviction review.
HIMS portfolio position -39% — I previously flagged for TRIM. Position remains underwater and thesis (DTC pharma disruption + GLP-1 compounding tailwind) is being challenged by FDA enforcement on compounding. Action: TRIM remains.
CPI/Fed data gap: FRED returned null on Fed Funds Rate and 2Y Treasury today. Cannot assess curve shape with full confidence. Flagging.
Trump/AI executive action risk (Axios) — undefined but binary. Watching.
📋 POSITIONS SUMMARY
| Ticker | Status | Conviction | One-line thesis |
|---|---|---|---|
| MSFT | RECOMMEND | 8/10 | Diversified hyperscaler with Copilot monetization runway |
| NVDA | RECOMMEND | 8/10 | AI compute monopoly with software moat building |
| MELI | RECOMMEND | 7/10 | LATAM e-commerce + fintech compounder |
| LLY | MONITORING* | 7/10 | GLP-1 franchise with oral expansion catalyst |
| FSLR | MONITORING | 7/10 | U.S. solar policy moat, CdTe cost leader |
| BRK-B | MONITORING | 7/10 | Diversified compounder with cash optionality |
| KNSL | MONITORING | 7/10 | E&S specialty pure-play; cycle risk emerging |
| ADBE | MONITORING | 7/10 | Creative SaaS dominance under AI-disruption scrutiny |
| TTD, DDOG, NET, AXON, COST, CRWD, MDB, ITUB, NTRA, FDS, BWXT, CEG, GTLB, PAYC, HUBS, XOM, ZS, OKE, MKTX, ALRM, WDAY, HOOD, PCTY, SPSC, CSGP, DOCS, MEDP, AAON, EXPO | MONITORING | 6/10 | Various — see prior theses |
| DUOL, CELH, CAVA, KTOS, FICO, DEEP | MONITORING | 5/10 | Various — see prior theses |
*LLY flagged for upgrade review.
💼 YOUR PORTFOLIO
| Ticker | Shares | Cost | Current | P&L | Conv. | Action |
|---|---|---|---|---|---|---|
| AAPL | 200 | $50.46 | $280.14 | +455% | 8/10 | HOLD |
| GOOGL | 32 | $320.20 | $385.69 | +20.5% | 9/10 | STRONG HOLD |
| MKL | 13 | $909.50 | $1,779.36 | +95.6% | 7/10 | HOLD |
| ALTO | 3,000 | $1.04 | $5.43 | +422% | 4/10 | TRIM |
| UNH | 15 | $314.29 | $368.78 | +17.3% | 7/10 | HOLD |
| FSLR | 10 | $186.18 | $211.71 | +13.7% | 7/10 | HOLD |
| U | 100 | $25.98 | $27.13 | +4.4% | 6/10 | HOLD |
| BABA | 40 | $127.86 | $131.50 | +2.8% | 7/10 | HOLD |
| SEG | 210 | $22.91 | $22.29 | -2.7% | 5/10 | HOLD |
| TSLA | 83 | $419.09 | $390.82 | -6.7% | 5/10 | TRIM |
| SOUN | 270 | $11.13 | $9.56 | -14.1% | 6/10 | HOLD |
| PLTR | 12 | $176.97 | $144.07 | -18.6% | 6/10 | HOLD |
| ISRG | 5 | $578.24 | $457.78 | -20.8% | 8/10 | HOLD |
| HIMS | 200 | $45.12 | $27.41 | -39.3% | 5/10 | TRIM |
Portfolio commentary: